Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

The company release and SEC exhibit support improved operating evidence, but PLD's October 15 close was about 2.7% lower at $126.92 according to [MarketBeat's historical quote](https://www.marketbeat.com/stocks/NYSE/PLD/forecast/), close to the packet's $126.94 adjusted-close anchor. The negative reaction should not be assigned a single cause without stronger reporting. No verified post-print analyst revisions were found; social coverage is absent, and zero-valued sentiment fields are unavailable placeholders rather than measured readings. This T+1 assessment remains cautious despite the positive deterministic prior.

The October 15 anchor rose 0.73% on that date, but this is not a verified post-earnings reaction. Company results and third-quarter guidance remain unconfirmed; consensus sources differ, and no post-print target or estimate changes were verified. Sentiment metrics other than low observed headline activity are unavailable; zero values above denote unavailable data, not neutral readings. The deterministic positive prior is tempered because its scheduled T+1 earnings premise was not corroborated.

The recent company announcement concerns timing, not third-quarter performance. There is no post-release price reaction, earnings surprise, guidance revision or verified analyst target change to assess as of October 16. The packet's October 15 close is therefore a pre-results anchor. Sentiment metrics other than low observed headline activity are unavailable; zeros above denote unavailable data, not measured neutrality. The deterministic prior is neutral, with very low evidence quality (0.08) and high uncertainty (0.906).

The Q3 print improved the prior positive thesis, consistent with the deterministic positive directional prior and 0.685 thesis-change score, but this T+1 view remains provisional. Shares were reported down 1.58% pre-market on margin concerns before the October 15 session closed about 3.2% higher; that is a reversal, not proof the earnings reaction will persist. No verified post-print analyst revision was available. Social, options, short-interest and employee measures are unavailable; zero values in the sentiment object denote unavailable data, not neutral observations.

Initial coverage reported an after-hours rise of nearly 7% following the October 15 release, but that is not evidence the move held. The packet's $68.98 anchor is up about 3.8% from the prior close. Earnings-surprise estimates conflict across sources, and verified analyst revisions are unavailable; zero values in optional sentiment fields indicate unavailable data, not neutral readings.

T+3 evidence is mixed rather than decisively bullish: Citi beat the cited Q3 revenue and EPS estimates and raised its return outlook, but the stock fell about 3.4% intraday on October 13 and several post-print targets were cut. Benzinga reported $123.20 trading on October 14, broadly consistent with the packet's $123.21 October 15 anchor; the initial sell-the-news move had not meaningfully reversed. The Goldman note attributed weakness mainly to positioning, while other coverage focused on sequential softness. Social, options-skew, short-interest and employee-score data were unavailable; their zero placeholders above are not measured readings. Sources: https://www.investing.com/news/stock-market-news/why-is-citigroup-stock-sliding-today-93CH-4947285 ; https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62363435/citigroup-analysts-slash-their-forecasts-following-q3-results ; https://www.tipranks.com/news/the-fly/citi-price-target-lowered-to-155-from-156-at-goldman-sachs-thefly-news